renal cell carcinoma

With integrated data for thousands of TCGA tumors, teams explored cancer subtypes, searched for prognostic insights, began mapping immune cell interactions, and more.

The company expects to be able to offer at least one test commercially by the end of this year or early next, with research now starting on two others.

A pair of papers point to potential gut microbial contributions to checkpoint blockade immunotherapy response in individuals with lung, kidney, or skin cancer.

This Week in Cell

In Cell this week: variants linked to enhanced branching among tomatoes, innate and adaptive immune response to Zostavax vaccination, and more.

The researchers used mass cytometry to characterize dozens of markers in 3.5 million immune cells in samples from 73 clear cell renal cell carcinoma patients.

The companies will use Personalis' ACE ImmunoID next-generation sequencing platform to analyze tumor samples from clinical trials of Argos' drug.

In Genome Biology this week: variants linked to disorders of sex development, new candidate genes for ciliopathies, and more.

A renal cell carcinoma study revealed increased metabolic gene expression in PD-L1-positive tumors from individuals who did not respond to nivolumab.

In Genome Biology this week: methylation changes in aging, single-cell RNA sequencing of renal cell carcinoma tumor, and more.

A Baylor College of Medicine-led team uncovered nine genomic subtypes of kidney cancer that may help direct patients' treatments.

Pages

American scientists find themselves once again warning the Trump administration not to dismiss science, the New Yorker report.

A new study suggests CRISPR could be used to save coral reefs from dying off, Forbes reports.

Researchers have found that the i-motif shape of DNA previously observed in the lab also exists in human cells, and that it may serve a purpose.

In PNAS this week: a genomic, transcriptomic, and metabolomic analysis of the tea plant, Arabidopsis thaliana's adaptations to specific local environments, and more.